Mylan to acquire Aspen's thrombosis business in Europe

The transaction will further complement and expand Mylan's complex injectables offering and presence in hospitals.
Mylan has agreed to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for EUR 641.9 million.
The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
These products had combined net sales of approximately EUR 231 million for the 12 months ended 30 June 2020.
According to Mylan President, Rajiv Malik, the acquisition will make Mylan the second largest supplier of these products to patients in Europe. It will also bolster the company's existing commercial infrastructure to further expand access to complex injectables.
He said: "By adding to our highly experienced sales and marketing team, we will further strengthen our current reach in hospitals and enhance the future growth of our biosimilars franchise in Europe."
Mylan Executive Chairman Robert J. Coury commented: "As we continue toward the launch of Viatris, we remain committed to executing on opportunities that will not only add to Mylan's growth, but that also will be consistent with our vision for Viatris under the Global Healthcare Gateway, which we believe will establish the new company as a true Partner of Choice."
Viatris is the chosen company name for the merger between Mylan and Pfizer's Upjohn.
Aspen will retain manufacturing and product supply responsibilities and will supply Mylan with finished product.
Upon closing of the transaction, which is expected to be completed before 31 December 2020, Mylan expects to fund an upfront payment of EUR 263.2 million to Aspen and to make the final deferred payment of EUR 378.7 million on 25 June 2021.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance